marketing valuation for Vor’s Telitacicept
Although Telitacicept has a clear advantage in terms of actual clinical progress, it achieved very promising result and has been approved in China for 3 major indications:gMG,SLE, and RA. In global Phase III trials, Telitacicept is lagging behind its competitors in all indications except for gMG. This is largely due to the insufficient cash flow of both Vor Bio and RemeGen.
It is also worth noting that Atacicept, as an earlier dual-target drug acting on BAFF+APRIL, may pose a patent threat to Telitacicept; industry experts might have a better judgment on the specific situation. As a newer generation drug, Povetacicept may potentially surpass Telitacicept in efficacy. Fortunately, neither of these two drugs currently shows signs of development in gMG. Overall, due to its own issues, Telitacicept might be an early bird that catches the worm late. However, it may still achieve good results in gMG. The gMG market is projected to reach approximately USD 3 billion by 2030, but there are many competitors. Under the most conservative assumption, Telitacicept could secure a 20% market share.
